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in patients with impaired lung defenses, and established infection may 
lead to deterioration in already borderline lung function or in a co- 
morbid condition. Some patient? also harbor bacteria in their ainvays 
when in a stable condtion, and this stimulates chronic inflammation. 
We do not know whether chronic infection contributes to decline 
in lung function, or to the frequency of exacerbations. Significant 
benefit from antibiotics has been demonstrated in patients with 
moderate to severe exacerbations defined by increased dyspnea, 
sputum production and sputum purulence. The prevalence of resist- 
ance to commonly prescribed beta-lactam and macrolide antibiotics 
in the bacterial pathogens causing exacerbations has increased. 
Antibiotics should be targeted at  those patients with more severe 
exacerbations and risk factors contributing to poor outcome; treat- 
ment is usually empirical and new agents, such as moxifloxacin,. are 
more successful in terms of bacteriologic eradication. Future studies 
should compare new and standard agents in patients with more severe 
disease, and consider using new modes of evaluation. 
Sinusitis overview 
R. Siegert. Ear, Nose and Throat Department, University of Luebeck, 
Luebeck, Germany 
Introduction: Acute sinusitis is associated with significant morbidity 
and represents an important cause of primary care practitioner 
consultation. The primary cause of acute sinusitis is viral or bacterial 
infection. In recent years, there has been a significant increase in 
resistance rates in the major causative bacterial pathogens of acute 
sinusitis (i.e. Streptococcus pneumoniae, Haemophilus injuenzae and 
Moraxella catarrhalis); hence, it is important that new agents are 
available to provide broad and potent empirical coverage of all 
possible causative pathogens. Moxifloxacin is a novel 8-methoxy- 
quinolone with excellent in vitro activity against all potential respira- 
tory pathogens and a good pharmacokinetic/pharmacodynamic 
profile. Moxifloxacin has been shown to achieve rapid and high 
penetration (with levels several-fold in excess of the MICYOS of the 
causative pathogens of sinusitis for at least 36 h post-dosing) into the 
sinus tissues following oral, 400-mg doses. 
Methods: This presentation will review data from a recent meta- 
analysis comparing the results of four n~ultinational clinical trials in 
patients with acute sinusitis treated with either 400 mg of moxi- 
floxacin or a comparator (cefuroxime). 
Results: The meta-analysis revealed that the mean eradication rate 
for all isolates combined (96%) is in accordance with the high clinical 
efficacy of moxifloxacin (96%) resolution/iniprovement). The bac- 
teriologic etiology for cefuroxime-treated patients was comparable to 
that of the moxifloxacin-treated population, with slightly lower 
resolution/improvement (90%) and eradication (93%) rates for 
cefuroxime. The modal moxifloxacin MIC was 0.25 nig/L for S. 
pneumoniae, 0.064 mg/L for H .  iq'henzae and 0.125 mg/L for M .  
catarrhalis. 
Conclusions: Moxifloxacin was highly successful, in terms of 
both clinical efficacy and bacteriologic eradication rates, in the 
treatment of acute sinusitis. 
[?TiEl Safety profile of moxifloxacin 
R. Stahlniann. University Hospifal Benjamin Frankliw, Freie 
Uuiiwsitaer Berlin, Berlin, Germany 
Moxifloxacin IS a new 8-methoxyquinolone with excellent in vitro 
Gram-positive and Gram-negative activity and a promising 
pharmacokinetic/pharmacodynamic profile. This presentation will 
summarize the current knowledge surrounding fluoroquinolone 
toxicity and will review the results of a recent meta-analysis of the 
moxifloxacin clinical safety database comprising a total of 20 phase I1 
and Ill trials. 
Data from 4926 patients with exposure to moxifloxacin and 3415 
patients with exposure to comparators revealed that the incidences of 
adverse drug reactions (ADRs) were comparable among all treatment 
groups. The majority of ADRs were mild and transient, and no 
unexpected severe reactions occurred. The overall ADR discon- 
tinuation rate observed with moxifloxacin was 3.8%. The most 
frequently reported adverse events in patients treated with moxi- 
floxacin were nausea (7.2%) and diarrhea (5.7%) with low dis- 
continuation rates (0.8% and 0.5% respectively); dizziness was 
reported by 2.8% of patients (discontinuation rate 0.5%). Moxi- 
floxacin is a photostable fluoroquinolone and there was no drug- 
related case of phototoxicity. 
As is the case with all new drugs, at present no clear-cut statement 
can be made about rarely occurring adverse reactions (at incidences 
of <0.1%). However, analysis of this rather large clinical database 
indicates that the safety and tolerability profile of moxifloxacin com- 
pares favorably with other quinolones recognized to be well tolerated 
(e.g. ciprofloxacin). 
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Bias associated with discrepant analysis 
A. Hadgu, Centersfor Disease Control, Division of STD Prevention, 
Atlanta, GA, lJS4 
The purpose of this presentation is to show that the sensitivity and 
specificity estimates obtained by 'discrepant analysis' are upwardly 
biased. Discrepant analysis is a widely used technique that attempts 
to provide estimates of sensitivity and specificity in the presence of 
an imperfect gold standard. Discrepant analysis has been used in the 
evaluation of Chlamydia tradtomalis, Neisseria gonorrhoeae, Clostridirrm 
d$cik, Mycobacteriron fubercuIosis, k@onella species, Toxopplasma gondii, 
Helicobacter pyluri, etc. This technique has been applied by many 
researchers to estimate the sensitivity and specificity of DNA-ampli- 
fication tests such as the plasmid-based ligase chain reaction (LCR) 
and polymerase chain reaction (PCR) tests. Moreover, earlier pack- 
age inserts of some of the DNA-amplification tests contain estimates 
of sensitivity and specificity based on 'discrepant analysis'. Even if one 
employs a periect test to resolve the discrepant results, discrepant 
analysis estimates of test sensitivity and specificity are still biased. 
Thus, this technique should not be adopted for evaluating the 
performance of a diagnostic test. 
Quality control of nucleic acid amplification 
methods 
G.T. Noordhoek. Public Healfh Laboratory, Medical Microbiology, 
Leeuwarden, Netherlands 
Diagnostic tests based on nucleic acid amplification (NAA) are now 
generally applied in clinical microbiology laboratories. The sensitivity 
and specificity of the NAA-based tests provide a powerful tool for 
rapid detection, identification and quantification of niicroorganisins. 
However, specially when low numbers of organisms have to be 
detected, false-negative and false-positive results may occur and the 
reliability of the methods is sometimes questionable. Quality control 
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studies have shown that the interpretation of results obtained with 
NAA techniques should be carried out with the greatest caution. For 
good laboratory performance, a test should be monitored by negative 
and positive controls for each step of the procedure in every run. In 
order to avoid false-positive results through contamination with 
aniplicons, the application of an anti-contamination system is obliga- 
tory Inhibition of the aniplification reaction should be nionitored by 
the use of an interndl control in each sample. Even with these 
measures, cross-contamination between samples occurs every now 
and then, or target DNA/RNA may be lost during pretreatment 
procedures. To obtain optimal performance, training of laboratory 
\taff nceds attention and autoniation of procedure\ should be 
introduced whenever possible. International availahle standards are 
required to estiiiidte the detection level ofa  method and the variation 
between laboratories. Regularly organized performance studies will 
help to improve the quality of NAA-based tests for application in the 
clinical laboratory. 
Is1951 Viral central nervous system (CNS) infections- 
diagnostic strategies 
S. Read. A!Jirropatltolo,qy Ltd., Inst. of Rcsrarch and Develop. 
Birni inglirharn , IIK 
P C R  assays have been evaluated in the diagnosis of suspected viral 
CNS disease in two series ofpatients. The initial ainis were to identify 
which virures cmse CNS infection in the UK, to design assays with 
good utility for routine use, and to assess the diagnostic accuracy of 
PCR of cerebrospinal fluid (CSF). 
It? r/ie+rsr serifs, 2 . 3 3  CSF specimens iuere rested. I ' i d  nircleir arid u m  
dcrccrcd i n  6.6"b utrd j w r  sers of primers detected 9406 .f the p~xitii,e 
spcciirrcws. .4 puricrrt irifli '1 positiw r i ~ ~ u l t  u~as 88 rimrs as likcly to h n i v  t i  
drfirrirr diqno.~is 4 vird it!l;.rrion uf the CNS as a parierzr with a rzrpriiv 
PCR r w r l r .  -4 r r g a t i i v  PCR r d f  could br uscd with niod~ratr  confiderice 
ro nrlc otrr a dia'qtiosii ~$iirol  ir!fcrtion $the CNS. 
The  second series of 10x3 CSF specimens was tested with P C R  
assays with higher molecular sensitivities and improved utility for 
routine use. Multiplex assays were developed, one detecting the niost 
frequent c~iuses of viral meningitis and encephalitis in the UK (HSV- 
1, HSV-2, VZV and enteroviruses), and another detecting viruses 
that cause CNS disease in the immunosuppressed (CMV, EUV and 
HHV6). Viral nucleic acid was detected in 8.4% of the specimens 
and, compared to the accepted relative incidence of viral etiologies 
of aseptic mcningitis, HSV-2 detection was more frequent. 
We have concluded that. with appropriate multiplex assays, P C R  
can be routinely and economically applied as the first-line laboratory 
test for the diagnosis of viral infections of the CNS and that thls is 
now the 'gold standard' approach to this problem. 
Chronic hepatitis: new approaches in 
diagnosis and treatment 
(s1981 Molecular antiviral strategies 
E von Weizsaecker. h fed .  Lhiu k-liriik, Freilncg, Ccrniauy 
As a leading cause of liver cirrhosis and hepatocellular carcinoma, 
chronic viral hepatitis poses a major healthcdre problem. The vast 
majority of all cases of chronic viral hepatitis are due to hepatitis B 
or C virus infection. Whilr 5ensitive diagnostic tests are available for 
both viral infections, therapy remains unsatisfactory. In the search for 
new therapeutic options, several genetic antiviral Strategies are 
currently being explored. Apart froin DNA v.iccination, 'in attractive 
concept IS blocking viral gene expression or function within the cell 
('intracellular immunization'). Antisense nucleic acids are desibmed to 
specifically bind to RNA,  rerulting in the formation of l1NA-IINA 
(antitense DNA) or RNA-KNA (antisense KNA) hybrids with an 
arrest of K N A  replication, reverse transcription or messenger KNA 
translation. Antisense effects can be potentiated by degradation of 
R N A  in KNA-DNA hybrids by cellular RNases. Ribozymes 
('ribonucleic acid enzynies') are small ILNA molecules that catalyze 
the sequence-specific cleavdge of a given tat-get KNA. liiterferiiig 
peptides or proteins, including single-chain or  whole non-secrcted 
antibodies, are aimed at the specific interference with the assenihly 
or  function of viral structural or non-ctructural protenic. While cell- 
culture experiments have yielded encouraging rewlts, experimental 
studies in animal iiiodels will be needed to fully assess the ther'ipeutic 
potential of these molecular antiviral strategic.c.) 
m] DNA immunization for HBV infection 
M.L. Michel. Pmtenr Instirure, Ih'SERhl 
DNA vaccines induce immune responses against antigens synthesized 
in vivo after direct introduction of the DNA's encoding sequcnces. 
This unique approach to ~niniunizdtion may overcome the deficits of 
traditional antigen-based approaches and provide safe and effective 
prophylactic and therapeutic vaccines. 
Systemic itnniunization of mice by Intramuscular injection of 
plasniid DNA expressing hepatitis B virus (HBV) envelope proteinc 
and HUV surface antigen (HBsAg) inducec rapid, strong and 
sustained huinoral and cell-mediated ininiune responw. Antibod~es, 
which are initially of the IgM and then of the Ig<; irotype 
(predominantly lgG:,J, recognize several of the U-cell cpitopes 
present on the S, preS2 or preSl domains of the envelope protcins. 
High titers of anti-HL3s are present by 1-8 weeks md persist for at 
least 17 nionths after a single DNA injection, although they c m  be 
boosted 1 0-fold by a second Injection of DNA, or sonicwhat Ic\s by 
injection of a recombinant HUsAg protein. A strong cellular iniiiiune 
response IS induced hy the l>NA-baced ininiiinization, with hlgh 
levels of CTL and CTL precursors being detected by 1 week and 
being maintained for wveral months. A DNA vaccines also acts d\ its 
own adjuvant, owing to  the presence of bacterial iiiimurioctiiiiu1ato1-y 
CpG iriotik Such seqiiences present in the plasnnd backbone 
promote a Thl-like pattern of cytokine production dominated by 
IL-32 and 1FN-y with little tecretion of Th2  cytokiiirr. 
Ininiunization of mice that are transgenic for the human HLA- 
A2.1 molecule and knock-out for inurine M H C  class 1 moleculec 
with DNA-encoding HBsAg shows that epitopes presented .ifter in 
vivo procesing in HLA-A2 T g  mice are very siniila to those 
generated in huiiians during HBV infection. 
Owing to the endogenous synthesis of antigen, processing into 
relevant epitopes and the induction of CDX CTLs, DNA vciccines 
may be useful to treat individuals chronically infected with HUV As 
a model to study the possibility of inducing an immune response in 
HBV chronic carriers that could control the infection, we uscd trans- 
genic mice (Tg) th'it constitutively express the HBsAg in the liver 
only. These T g  inice secrete large amounts of HBsAg into the seruni 
without antibody production and they \how no liver pathology. 
Using a plasmid DNA encoding the s n i d  and the niiddlc HBV 
envelope protein, we were able to gencrate anti-HBs antibodies III 
these transgenic mice, which in turn induce the clearance of  circu- 
lating HBsAg. This elimination, which was persistent, war also 
correlated with d decrease or  a disappearance of the HBV messenger 
R N A  from the liver. Experinients involving the transfer of frac- 
tionated HbsAg-primed spleen cells obt.iined from DN A-iniiiiunized 
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